NRG-BR008/HERO study: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer Journal Article
| Authors: | Braunstein, L. Z.; Mitchell, M. P.; Bandos, H.; Sikov, W. M.; Khan, A. J.; Chen, P. Y.; Ganz, P. A.; Jagsi, R.; White, J. R.; Cecchini, R. S.; Kang, H.; Puhalla, S. L.; Bolton, K. L.; Connolly, E. P.; Stringer-Reasor, E. M.; Gergelis, K. R.; Julian, T. B.; Mamounas, E. P.; Wolmark, N. |
| Article Title: | NRG-BR008/HERO study: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer |
| Abstract: | HER2-positive breast cancer historically had the highest rates of recurrence but has substantially improved outcomes with the advent of targeted anti-HER2 therapies. NRG-BR008/HERO is a Phase III randomized trial evaluating whether adjuvant radiotherapy remains beneficial in low-risk HER2-positive breast cancer treated with HER2-targeted therapies. Patients are randomly assigned to receive either standard radiotherapy or observation after breast-conserving surgery. The primary endpoint is a recurrence-free interval, with secondary endpoints including 7-year ipsilateral breast recurrence, disease-free survival, overall survival, and patient-reported outcomes including worry and breast pain. Clinical Trial Registration: NCT05705401 (ClinicalTrials.gov). © 2025 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; controlled study; human tissue; treatment outcome; middle aged; overall survival; clinical trial; mortality; adjuvant therapy; metabolism; quality of life; randomized controlled trial; radiotherapy dosage; radiotherapy; epidermal growth factor receptor 2; randomized controlled trials as topic; pathology; breast neoplasms; clinical trials, phase iii as topic; breast tumor; receptor, erbb-2; phase 3 clinical trial; adjuvant radiotherapy; lumpectomy; randomized controlled trial (topic); erbb2 protein, human; phase 3 clinical trial (topic); patient-reported outcome; her2-targeted therapy; oncological outcomes; human epidermal growth factor receptor 2 positive breast cancer; her2-positive breast cancer; humans; human; male; female; article; breast-conservation therapy; breast cancer treatment; breast radiotherapy; adjuvant breast radiotherapy; quality of life outcomes |
| Journal Title: | Future Oncology |
| Volume: | 21 |
| Issue: | 16 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2025-01-01 |
| Start Page: | 2017 |
| End Page: | 2025 |
| Language: | English |
| DOI: | 10.1080/14796694.2025.2511586 |
| PUBMED: | 40574381 |
| PROVIDER: | scopus |
| PMCID: | PMC12218515 |
| DOI/URL: | |
| Notes: | Source: Scopus |
